# Regeneron Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 43.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/regeneron-pharmaceuticals-inc-consensus-buy-rating-and-43-0-upside-potential/4121184034
- Published: 2025-01-17T13:24:09+00:00
- Author: Charlotte Edwards

**Regeneron Pharmaceuticals, Inc.** with ticker code (REGN) have now 25 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $1,230.00 and $565.00 with the average target price
sitting at $1,005.65. Given that the stocks previous close was at $703.43 this indicates
there is a potential upside of 43.0%. The 50 day moving average now sits at $749.20
and the 200 moving average now moves to $960.76. The total market capitalization
for the company now stands at 76.18B. The stock price is currently at: $693.23 USD

 The potential market cap would be $108,908,951,383 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 17.15, revenue per share of $128.69
and a 7.41% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers,
invents, develops, manufactures, and commercializes medicines for serious diseases.
Its commercialized medicines and product candidates in development are designed 
to help patients with eye diseases, allergic and inflammatory diseases, cancer, 
cardiovascular and metabolic diseases, pain, hematologic conditions, infectious 
diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection,
Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab)
Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza(
evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection,
ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept)
Injection for Intravenous Infusion. The Company also provides Expresse service assurance
and CloudCheck WiFi experience management solutions.

Share on: